TScan Therapeutics(TCRX) - 2025 Q3 - Quarterly Results

TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update Reached agreement with FDA on pivotal study design for TSC-101 following productive end of Phase 1 meeting Data from ALLOHA™ Phase 1 heme trial to be presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition Made the strategic decision to prioritize clinical development of the heme program and initiate preclinical development of in vivo-engineered TCR-T for solid tumors Exhibit 99.1 U ...